INCYTE CORP
About INCYTE CORP
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $5.1B
- Net income
- $1.3B
- Total assets
- $7.0B
- Market cap
- $20.5B
- Gross margin
- 93.1%
- Operating margin
- 16.8%
- Net margin
- 16.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $3.7B
- Cost of revenue
- $255.0M
- Gross profit
- $3.4B
- Operating expenses
- $2.8B
- Operating income
- $620.5M
- Income tax
- $236.6M
- Net income
- $597.6M
- EPS (basic)
- $2.67
- EPS (diluted)
- $2.65
Balance sheet
- Total assets
- $6.8B
- Current assets
- $4.6B
- Total liabilities
- $1.6B
- Current liabilities
- $1.2B
- Shareholders’ equity
- $5.2B
Cash flow
- Operating cash flow
- $496.5M
- Investing cash flow
- -$207.7M
- Financing cash flow
- -$20.0M
- Net cash flow
- $262.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $20.5B
- P/E ratio
- 38.0
- EPS (diluted)
- $2.65
- Shares outstanding
- 203.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 3, 1993
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $1.3B in FY2025.
- Revenue grew 71% from FY2019 to FY2023.
- Gross margin of 93.1%, net margin 16.2%.
- Trading 9% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 38.0.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review INCYTE CORP.
Write a review
News about INCYTE CORP
News & sentiment via Polygon.io
